Switzerland

Idorsia Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Idorsia Successfully Completes the Offering of New Shares Thereby Securing Funding for the Company’s Growth Plan

Lead Product(s): Aprocitentan

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $341.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering May 20, 2020

Details:

The net proceeds from this offering will help Idorsia to prepare to launch its first commercial product and continue to fund the development of its pipeline candidates including aprocitentan, clazosentan and lucerastat, as well as its early-stage and preclinical pipeline.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran

Lead Product(s): Inclisiran

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2020

Details:

Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials shows inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Novartis announces NEJM publication of three pivotal trials

Lead Product(s): Inclisiran

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2020

Details:

Inclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD).

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

Idorsia Pharmaceuticals

Idorsia Successfully Completes the Offering of New Shares Thereby Securing Funding for the Company’s Growth Plan

Novartis Pharmaceuticals Corporation

Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran

Novartis Pharmaceuticals Corporation

Novartis announces NEJM publication of three pivotal trials